InvestorsHub Logo
Followers 135
Posts 18032
Boards Moderated 7
Alias Born 05/28/2009

Re: sevenOdouble post# 4163

Sunday, 02/20/2011 2:13:30 PM

Sunday, February 20, 2011 2:13:30 PM

Post# of 6280
I disagree. Any analysis that simpy tracks trailing quarters' numbers, without factoring in the projected sharp increases in revenue going forward as a result of the commercial roll-out of Nuedexta, is flawed.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.